

# United Kingdom of Great Britain and Northern Ireland Tuberculosis profile

Population 2015

65 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.3 (0.29–0.3)	0.46 (0.46–0.46)
Mortality (HIV+TB only)	0.038 (<0.01–0.21)	0.06 (0–0.32)
Incidence (includes HIV+TB)	6.6 (6–7.2)	10 (9.2–11)
Incidence (HIV+TB only)	0.31 (0.25–0.38)	0.48 (0.38–0.59)
Incidence (MDR/RR-TB)**	0.11 (0.072–0.15)	0.17 (0.11–0.23)

Estimated TB incidence by age and sex (thousands)*, 2015			
	0-14 years	> 14 years	Total
Females	0.25 (0.15–0.35)	2.5 (1.9–3)	2.7 (2.1–3.4)
Males	0.3 (0.21–0.38)	3.6 (2.8–4.3)	3.9 (3.1–4.7)
Total	0.55 (0.43–0.66)	6 (5.7–6.4)	6.6 (6–7.2)

TB case notifications, 2015	
Total cases notified	6 240
Total new and relapse	5 854
- % tested with rapid diagnostics at time of diagnosis	5%
- % with known HIV status	81%
- % pulmonary	53%
- % bacteriologically confirmed among pulmonary	76%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2015	89% (81–98)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.05 (0.04–0.07)

TB/HIV care in new and relapse TB patients, 2015		Number	(%)
Patients with known HIV-status who are HIV-positive			
- on antiretroviral therapy			

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			58 (39–77)
Estimated % of TB cases with MDR/RR-TB	1.4% (0.98–2)	3.4% (1.1–7.9)	
% notified tested for rifampicin resistance	58%	51%	3 759
MDR/RR-TB cases tested for resistance to second-line drugs			53
Laboratory-confirmed cases		MDR/RR-TB: 57, XDR-TB: 10	
Patients started on treatment ****		MDR/RR-TB: 62, XDR-TB: 10	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	81%	6 512
Previously treated cases, excluding relapse, registered in 2014	72%	450
HIV-positive TB cases, all types, registered in 2014		
MDR/RR-TB cases started on second-line treatment in 2013	65%	77
XDR-TB cases started on second-line treatment in 2013	33%	3

TB preventive treatment, 2015	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016	
National TB budget (US\$ millions)	


\* Ranges represent uncertainty intervals

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history


\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB